Abbott Laboratories annual gross profit for fiscal TTM was $25.4 billion, an increase of 3.4% from $24.6 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Gross Profit (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Profit | $25.4B | $24.6B | $21.3B | $20.0B | $22.3B | $23.2B | $17.4B | $16.7B | $15.8B | $13.1B | $11.2B | $11.0B | $10.5B | $9.9B | $10.9B | $23.4B | $20.6B | $17.6B | $17.0B | $14.6B | $12.8B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Gross Profit (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Gross Profit | $6.3B | $6.5B | $6.3B | $6.3B | $5.4B | $5.6B | $5.4B | $5.3B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More ABT metrics: Revenue · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All ABT financial statements → Interactive ABT charts →
About TickerBase · Data methodology & sources